RA Outcomes Improved in KURAMA Cohort - Summary - MDSpire

RA Outcomes Improved in KURAMA Cohort

Ten-year observational data showed lower disease activity and functional disability coinciding with broader use of biologic and targeted synthetic therapies.

  • By

  • Andrea Surnit

  • May 22, 2026

  • 4 min

Share

Objective:

To analyze the long-term outcomes of patients with rheumatoid arthritis (RA) in the KURAMA cohort over a 10-year period.

Key Findings:
  • Include detail about methotrexate use remaining above 60% throughout the study period.
Interpretation:

Remove unsupported conclusions regarding the sensitivity of the Disease Activity Score 28-C-reactive protein.

Limitations:
  • Explicitly mention the lack of generalizability due to the single-center nature of the study.
Conclusion:

Remove unsupported summary statements about the transition of therapeutic strategies.

Original Source(s)

RA Outcomes Improved in KURAMA Cohort

  • by Andrea Surnit

  • May 22, 2026

Related Content

Hair Repigmentation Reported With Baricitinib in Canities Subita

A single case suggests a possible benefit, but confounding factors and the off-label setting temper the conclusions.

7 Days Noninferior in Bacteremia

BALANCE compared 7 vs 14 days of treatment among hospitalized patients with bloodstream infections.

Targeting the synovial engine: next-generation engineered immune cells to eradicate pathogenic FLS in rheumatoid arthritis, with safety-first, selective designs